Free Trial
NASDAQ:CRMD

CorMedix Q2 2025 Earnings Report

CorMedix logo
$10.86 -0.21 (-1.90%)
Closing price 04:00 PM Eastern
Extended Trading
$10.88 +0.03 (+0.23%)
As of 07:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CorMedix EPS Results

Actual EPS
N/A
Consensus EPS
$0.17
Beat/Miss
N/A
One Year Ago EPS
N/A

CorMedix Revenue Results

Actual Revenue
N/A
Expected Revenue
$29.88 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

CorMedix Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Wednesday, August 13, 2025
Conference Call Time
8:30AM ET

Conference Call Resources

CorMedix Earnings Headlines

Brokerages Set CorMedix Inc (NASDAQ:CRMD) Target Price at $17.14
The End of Elon Musk…?
The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, and he's been proven right time and time again. And now, while the media focuses on Tesla's "demise," he's uncovered an AI breakthrough that's about to make Elon's doubters eat their words yet again. According to his research, if you listen to the media and miss out on Elon's newest breakthrough, it's going to cost you the fortune of a lifetime.
See More CorMedix Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like CorMedix? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CorMedix and other key companies, straight to your email.

About CorMedix

CorMedix (NASDAQ:CRMD). is a clinical-stage biopharmaceutical company dedicated to developing therapeutic and diagnostic products aimed at addressing hospital-acquired infections and associated complications in high-risk patient populations. Founded in 1985 and headquartered in Montville, New Jersey, the company focuses on innovative approaches that seek to prevent bloodstream infections, thrombosis and inflammation related to the use of indwelling medical devices. Its research-driven platform combines antimicrobial, anticoagulant and anti-inflammatory mechanisms to target serious, often life-threatening conditions in hospitalized patients.

The company’s lead product candidate, Neutrolin®, is an investigational catheter lock solution designed to reduce the incidence of catheter-related bloodstream infections and catheter occlusions in patients requiring long-term central venous access. Neutrolin combines a proprietary formulation of anticoagulant and antimicrobial agents that is intended to inhibit microbial colonization on catheter surfaces while maintaining patency. In addition to Neutrolin, CorMedix is advancing complementary programs that explore novel anti-infective molecules and diagnostic assays aimed at early detection or prevention of device-related infections.

CorMedix has pursued regulatory interactions and clinical development in the United States and Europe, engaging with healthcare institutions and academic centers to conduct pivotal studies. The company has established strategic partnerships with contract research organizations and distribution networks to support manufacturing scale-up, clinical trial enrollment and future commercialization. By leveraging global expertise and compliance with stringent regulatory standards, CorMedix aims to provide healthcare providers with new tools to lower infection rates and improve patient outcomes in intensive care, oncology and hemodialysis settings.

CorMedix’s leadership team brings decades of combined experience in pharmaceutical development, clinical operations and regulatory affairs. Guided by a seasoned board of directors and scientific advisors, the company integrates expertise in infectious disease, critical care medicine and drug manufacturing. This multidisciplinary approach underpins CorMedix’s commitment to advancing its pipeline candidates toward regulatory approval and ultimately transforming care paradigms for patients at high risk of device-associated infections.

View CorMedix Profile

More Earnings Resources from MarketBeat